Rate Control in Atrial Fibrillation II (RATAFII)
Atrial Fibrillation, Permanent Atrial Fibrillation
About this trial
This is an interventional treatment trial for Atrial Fibrillation focused on measuring Rate control in atrial fibrillation, Beta blockers, Calcium channel blockers, Permanent atrial fibrillation, Management of atrial fibrillation, Atrial fibrillation and biomarkers, Arrhythmias, cardiac, Heart Diseases, Pathological processes, Diltiazem, Metoprolol, Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-1 Receptor Antagonists, Adrenergic beta-Antagonists, Anti-Arrhythmia Agents, Antihypertensive Agents, Autonomic Agents, Cardiovascular Agents, Membrane Transport Modulators, Molecular Mechanisms of Pharmacological Action, Neurotransmitter Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Sympatholytics, Therapeutic Uses, Vasodilator Agents, Troponins, NT-proBNP, Biomarkers
Eligibility Criteria
Inclusion Criteria:
- Above 18 years of age
- Symptomatic, permanent AF of at least three months duration
- Resting heart rate ≥80 bpm
- Signed informed consent
Exclusion Criteria:
- Congestive heart failure
- Ischemic heart disease
- Hypotension (Systolic blood pressure <100 mmHg)
- Treatment with class I or III antiarrhythmic drugs
- Severe hepatic or renal failure
- Pregnancy or lactation
- Hypersensitivity or contradictions to study drugs
- Atrio-ventricular conduction disturbances
- Thyrotoxicosis
- Life limiting disease or substance abuse which may affect participation
Sites / Locations
- Vestre Viken Hospital Trust, Baerum Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Metoprolol
Diltiazem
Metoprolol, extended release tablets. 100 mg daily
Diltiazem, extended release tablets. 360 mg daily